BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
Moodys
Dow
Chubb
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Deloitte
Chinese Patent Office

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,062,652

« Back to Dashboard

Which drugs does patent 8,062,652 protect, and when does it expire?

Patent 8,062,652 protects SUPPRELIN LA and is included in one NDA.

This patent has three patent family members in three countries.
Summary for Patent: 8,062,652
Title:Compositions and methods for treating precocious puberty
Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Inventor(s): Kuzma; Petr (Princeton, NJ)
Assignee: Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:11/155,822
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;

Drugs Protected by US Patent 8,062,652

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,062,652

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2006009801 ➤ Subscribe
European Patent Office 1773293 ➤ Subscribe
Canada 2570960 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Colorcon
Queensland Health
Fuji
Covington
Chinese Patent Office
Merck
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot